Literature DB >> 18095118

Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays.

Naoki Kagawa1, Motohiko Maruno, Tsuyoshi Suzuki, Tetsuo Hashiba, Naoya Hashimoto, Shuichi Izumoto, Toshiki Yoshimine.   

Abstract

Medulloblastoma (MB) is the most frequent infratentorial malignant brain tumor in children. In contrast, primitive neuroectodermal tumor (PNET) is defined as a supratentorial malignant tumor generated from the cerebral hemisphere. These tumors have considerable histological overlap but have different clinical outcomes including overall survival period, recurrence rate, and chemosensitivity. We investigated the amplification and/or deletion of genes and the chromosomal gain and/or loss in 10 MBs and 3 PNETs with a genomic DNA microarray system. Genes that are frequently amplified in these both these tumors include MSH2, N-myc, AKT3, and EGFR. Amplifications of SNRPN, MYB, and PTEN are observed only in MB. The genes associated with Wnt/APC and Shh/PTCH pathways also have some aberrations. Common chromosomal aberrations include gains at 17q and 7q and losses at 17p. Minor chromosomal losses were also detected at 1p, 8p + q, 11p, 10p + q, 13q, 16q, and Xp + q in MB. SPNETs tend to contain fewer chromosomal and genetic abnormalities than MBs. In conclusion, there are gene expression and chromosomal differences between MBs and SPNETs. These differences may correlate with the prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18095118     DOI: 10.1007/s10014-006-0201-1

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  9 in total

1.  MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas.

Authors:  Ruth G Tatevossian; Bo Tang; James Dalton; Tim Forshew; Andrew R Lawson; Jing Ma; Geoff Neale; Sheila A Shurtleff; Simon Bailey; Amar Gajjar; Suzanne J Baker; Denise Sheer; David W Ellison
Journal:  Acta Neuropathol       Date:  2010-11-03       Impact factor: 17.088

Review 2.  Pediatric brain tumors: current treatment strategies and future therapeutic approaches.

Authors:  Sabine Mueller; Susan Chang
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 3.  Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Brain Pathol       Date:  2011-07-07       Impact factor: 6.508

4.  Reduced Expression of RNA Binding Protein CELF2, a Putative Tumor Suppressor Gene in Colon Cancer.

Authors:  Satish Ramalingam; Prabhu Ramamoorthy; Dharmalingam Subramaniam; Shrikant Anant
Journal:  Immunogastroenterology       Date:  2012

5.  KIF26B Is Overexpressed in Medulloblastoma and Promotes Malignant Progression by Activating the PI3K/AKT Pathway.

Authors:  Yajun Liu; Xi Zhang; Ruihan Pan; Xiaolong Liang; Qichang Liu; Chao Yang; Xu Li
Journal:  Anal Cell Pathol (Amst)       Date:  2022-07-12       Impact factor: 4.133

6.  Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.

Authors:  Tea Blom; Annariikka Roselli; Valtteri Häyry; Olli Tynninen; Kirmo Wartiovaara; Miikka Korja; Kristiina Nordfors; Hannu Haapasalo; Nina N Nupponen
Journal:  J Neurooncol       Date:  2009-09-25       Impact factor: 4.130

7.  Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.

Authors:  Hannah Johnson; Amanda M Del Rosario; Bryan D Bryson; Mark A Schroeder; Jann N Sarkaria; Forest M White
Journal:  Mol Cell Proteomics       Date:  2012-09-10       Impact factor: 5.911

8.  Diverse involvement of isoforms and gene aberrations of Akt in human lung carcinomas.

Authors:  Yoh Dobashi; Hiroyoshi Tsubochi; Hirochika Matsubara; Jun Inoue; Johji Inazawa; Shunsuke Endo; Akishi Ooi
Journal:  Cancer Sci       Date:  2015-05-08       Impact factor: 6.716

Review 9.  The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.

Authors:  Hazel A Rogers; Jasper Estranero; Keshni Gudka; Richard G Grundy
Journal:  Oncotarget       Date:  2017-01-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.